Enterobiome Inc. is developing microbiome treatments and health-functional foods with various effects using potential next-generation probiotics such as Akkermansia muciniphila and Faecalibacterium prausnitzii. Those bacterial species among human intestinal microorganisms that have been shown to have a causal relationship with incurable diseases through research in domestic and international. 

We have completed the construction of the world's largest library and selection of excellent seed strains, and we have the original technology for mass production and commercialization and have acquired a patent. Human application testing for Akkermansia Muciniphila's respiratory health (ETB-F01) has been completed, and human application testing for reduction of body fat, improvement of sensitive skin, and hair loss is currently in progress. 
Additionally, we are preparing for phase 1 clinical trials to develop microbiome-based medicines.

Enterobiome Inc. stepped forward to enter the market and we are in the process of obtaining Akkermansia muciniphila US certification NDA, GRAS, and Korean certification.
At the moment we are delighted to open a Licensing-out business including technical transfer and co-development partnership. Distributors are also welcome and we will have a good opportunity to start and set up a new business with Akkermansia muciniphila which is next-generation probiotics.

(주)엔테로바이옴(Enterobiome inc.)

Org chart

Teams

Offices